Hyaluronidase: Both a Tumor Promoter and Suppressor

Hyaluronan in Cancer Biology

Volumn , Issue , 2009, Pages 189-206

  Lokeshwar, Vinata B ^a   Selzer, Marie G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864307373     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374178-3.10011-0     Document Type: Chapter

References (93)

1. Aboughalia A.H. Elevation of hyaluronidase-1 and soluble intercellular adhesion molecule-1 helps select bladder cancer patients at risk of invasion. Arch Med Res 2006, 37:109-116.
2. Arming S., Strobl B., Wechselberger C., Kreil G. In vitro mutagenesis of PH-20 hyaluronidase from human sperm. Eur J Biochem 1997, 247:810-814.
3. Basu A., Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003, 538:41-47.
4. Beech D.J., Madan A.K., Deng N. Expression of PH-20 in normal and neoplastic breast tissue. J Surg Res 2002, 103:203-207.
5. Bertrand P., Courel M.N., Maingonnat C., et al. Expression of HYAL-2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer 2005, 113:207-212.
6. Bertrand P., Girard N., Duval C., et al. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer 1997, 73:327-346.
7. Botzki A., Rigden D.J., Braun S., et al. L-Ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor. X-ray structure and molecular modeling of enzyme-inhibitor complexes. J Biol Chem 2004, 279:45990-45997.
8. Chang N.S. Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun 2001, 283:278-286.
9. Chang N.S. Transforming growth factor-beta1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase HYAL-2 in L929 fibroblasts. BMC Cell Biol 2002, 3:8.
10. Chang N.S., Doherty J., Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003, 278:9195-9202.
11. Chang N.S., Pratt N., Heath J., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001, 276:3361-3370.
12. Chow G., Knudson W. Characterization of promoter elements of the human HYAL-2 gene. J Biol Chem 2005, 280:26904-26912.
13. Christopoulos T.A., Papageorgakopoulou N., Theocharis D.A., et al. Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma. Biochim Biophys Acta 2006, 1760:1039-1045.
14. Croix B.S., Rak J.W., Kapitain S., et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst 1996, 88:1285-1296.
15. Csoka A.B., Frost G.I., Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001, 20:499-508.
16. Csoka A.B., Frost G.I., Heng H.H., et al. The hyaluronidase gene HYAL-1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus. Genomics 1998, 48:63-70.
17. Csoka A.B., Frost G.I., Wong T., Stern R. Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett 1997, 417:307-310.
18. Delpech B., Laquerriere A., Maingonnat C., Bertrand P., Freger P. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res 2002, 22:2423-2427.
19. Deng X., Xiao L., Lang W., et al. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001, 276:23681-23688.
20. Ehrlich M. DNA methylation in cancer, too much, but also too little. Oncogene 2002, 21:5400-5413.
21. Eissa S., Kassim S.K., Labib R.A., et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 2005, 103:1356-1362.
22. Ekici S., Cerwinka W.H., Duncan R., et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004, 112:121-129.
23. Enegd B., King J.A., Stylli S., et al. Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery 2002, 50:1311-1318.
24. Franzmann E.J., Schroeder G.L., Goodwin W.J., et al. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL-1) in head and neck tumors. Int J Cancer 2003, 106:438-445.
25. Frost G.I., Mohapatra G., Wong T.M., et al. HYAL-1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000, 19:870-877.
26. Garg A., Anderson R.A., Zaneveld L.J., Garg S. Biological activity assessment of a novel contraceptive antimicrobial agent. J Androl 2005, 26:414-421.
27. Garg S., Vermani K., Garg A., et al. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 2005, 22:584-595.
28. Girish K.S., Kemparaju K. Inhibition of Naja naja venom hyaluronidase: role in the management of poisonous bite. Life Sci 2006, 78:1433-1440.
29. Godin D.A., Fitzpatrick P.C., Scandurro A.B., et al. PH-20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg 2000, 126:402-404.
30. Goss V.L., Cross J.V., Ma K., et al. SAPK/JNK regulates cdc2/cyclin B kinase through phosphorylation and inhibition of cdc25c. Cell Signal 2003, 15:709-718.
31. Gould S.F., Bernstein M.H. The localisation of bovine sperm hyaluronidase. Differentiation 1975, 3:123-132.
32. Green S.K., Francia G., Isidoro C., Kerbel R.S. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-159.
33. Hall C.L., Lange L.A., Prober D.A., Zhang S., Turley E.A. pp60(c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM. Oncogene 1996, 13:2213-2224.
34. Hardy C.M., Clydesdale G., Mobbs K.J., et al. Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH-20. Reproduction 2004, 127:325-334.
35. Haselsberger K., Radner H., Pendl G. Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase. Cancer Lett 1998, 131:109-111.
36. Hautmann S.H., Lokeshwar V.B., Schroeder G.L., et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001, 165:2068-2074.
37. Hautmann S., Toma M., Lorenzo-Gomez M.F., et al. Immunocyte and the HA-HAase urine tests for the detection of bladder cancer, a side-by-side comparison. Eur Urol 2004, 46:466-471.
38. Hilbe W., Auberger J., Dirnhofer S., et al. High rate of molecular alteration in histologically tumour-free bronchial epithelium of NSCLC patients detected by multicolour fluorescence in situ hybridisation. Oncol Rep 2006, 15:1233-1240.
39. Hobart K., Maier U., Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992, 21:206-210.
40. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer 2002, 102:212-219.
41. Ji L., Nishizaki M., Gao B., et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 2002, 62:2715-2720.
42. Junker N., Latini S., Petersen L.N., Kristjansen P.E. Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep 2003, 10:609.
43. Kerbel R.S., St Croix B., Florenes V.A., Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell 1996, 9:257-264.
44. Klocker J., Sabitzer H., Raunik W., Wieser S., Schumer J. Combined application of cisplatin, vindesine, hyaluronidase and radiation for treatment of advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 1995, 18:425-428.
45. Klocker J., Sabitzer H., Raunik W., Wieser S., Schumer J. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett 1998, 131:113-115.
46. Lepperdinger G., Mullegger J., Kreil G. HYAL-2-less active, but more versatile?. Matrix Biol 2001, 20:509-514.
47. Lin G., Stern R. Plasma hyaluronidase (HYAL-1) promotes tumor cell cycling. Cancer Lett 2001, 163:95-101.
48. Liu X., Yan S., Zhou T., Terada Y., Erikson R.L. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 2004, 23:763-776.
49. Lokeshwar V.B., Selzer M.G. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 2000, 275:27641-27649.
50. Lokeshwar V.B., Cerwinka W.H., Lokeshwar B.L. HYAL-1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 2005, 65:2243-2250.
51. Lokeshwar V.B., Cerwinka W.H., Isoyama T., Lokeshwar B.L. HYAL-1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 2005, 65:7782-7789.
52. Lokeshwar V.B., Estrella V., Lopez L., et al. HYAL-1-v1, an alternatively spliced variant of HYAL-1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 2006, 66:11219-11227.
53. Lokeshwar V.B., Gomez P., Kramer M., et al. Epigenetic regulation of HYAL-1 hyaluronidase expression, identification of HYAL-1 promoter. J Biol Chem 2008, 283(43):29215-29227. Oct 24; Epub 2008 Aug 21.
54. Lokeshwar V.B., Lokeshwar B.L., Pham H.T., Block N.L. Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 1996, 56:651-657.
55. Lokeshwar V.B., Obek C., Pham H.T., et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000, 163:348-356.
56. Lokeshwar V.B., Obek C., Soloway M.S., Block N.L. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997, 57:773-777. Erratum in: Cancer Res (1998). 58, 3191.
57. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL-1 hyaluronidase in prostate cancer. J Biol Chem 2001, 276:11922-11932.
58. Lokeshwar V.B., Schroeder G.L., Carey R.I., Soloway M.S., Iida N. Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 2002, 277:33654-33663.
59. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002, 95:61-72.
60. Lokeshwar V.B., Young M.J., Goudarzi G., et al. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL-1. Cancer Res 1999, 59:4464-4470.
61. Madan A.K., Yu K., Dhurandhar N., Cullinane C., Pang Y., Beech D.J. Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol Rep 1999, 6:607-609.
62. Maier U., Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J Urol 1989, 141:529-530.
63. Markovic-Housley Z.,, Miglierini G., et al. Crystal structure of hyaluronidase, a major allergen of bee venom. Structure 2000, 8:1025-1035.
64. Marsit C.J., Hasegawa M., Hirao T., et al. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. Cancer Res 2004, 64:8702-8707.
65. McLean G.W., Carragher N.O., Avizienyte E., et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005, 5:505-515.
66. Miller A.D. Identification of HYAL-2 as the cell-surface receptor for jaagsiekte sheep retrovirus and ovine nasal adenocarcinoma virus. Curr Top Microbiol Immunol 2003, 275:179-199.
67. Mingo-Sion A.M., Marietta P.M., Koller E., Wolf D.M., Van Den Berg C.L. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004, 23:596-604.
68. Mitra S.K., Hanson D.A., Schlaepfer D.D. Focal adhesion kinase, in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68.
69. Morey S.S., Kiran K.M., Gadag J.R. Purification and properties of hyaluronidase from Palamneus gravimanus (Indian black scorpion) venom. Toxicon 2006, 47:188-195.
70. Nagaraju S., Mahadeswaraswamy Y.H., Girish K.S., Kemparaju K. Venom from spiders of the genus Hippasa: biochemical and pharmacological studies. Comp Biochem Physiol C Toxicol Pharmacol 2006, 144(1):1-9. Sep; Epub 2006 May 22.
71. Paiva P., Van Damme M.P., Tellbach M., et al. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol 2005, 98:193-202.
72. Patel S., Turner P.R., Stubberfield C., et al. Hyaluronidase gene profiling and role of HYAL-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer 2002, 97:416-424. Erratum in: Int J Cancer98, 957.
73. Pham H.T., Block N.L., Lokeshwar V.B. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997, 57:778-783. Erratum in: Cancer Res57, 1622.
74. Pillwein K., Fuiko R., Slavc I., et al. Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett 1998, 131:101-108.
75. Pizzi S., Azzoni C., Bottarelli L., et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol 2005, 206:409-416.
76. Posey J.T., Soloway M.S., Ekici S., et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL-1) for prostate cancer. Cancer Res 2003, 63:2638-2644.
77. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004, 172:1123-1126.
78. Shuster S., Frost G.I., Csoka A.B., Formby B., Stern R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 2002, 102:192-197.
79. Simpson M.A. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol 2006, 169:247-257.
80. Skov L.K., Seppala U., Coen J.J., et al. At 2.0 Angstrom resolution: structural analysis of an allergenic hyaluronidase from wasp venom. Acta Crystallogr D Biol Crystallogr62. Structure of recombinant Ves 2006, v. 2:595-604.
81. Smith K.J., Skelton H.G., Turiansky G., Wagner K.F. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1997, 6(2 Pt 1):239-242.
82. Spruss T., Bernhardt G., Schonenberger H., Schiess W. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 1995, 121:193-202.
83. St Croix B., Man S., Kerbel R.S. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 1998, 131:35-44.
84. Stern M., Stern R. An ELISA-like assay for hyaluronidase and hyaluronidase inhibitors. Matrix 1992, 12:397-403.
85. Stern M., Longaker M.T., Adzick N.S., Harrison M.R., Stern R. Hyaluronidase levels in urine from Wilms' tumor patients. J Natl Cancer Inst 1991, 83:1569-1574.
86. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) 2005, 53:372-382.
87. Stern R., Jedrzejas M.J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006, 106:818-839.
88. Suri A. Sperm specific proteins - potential candidate molecules for fertility control. Reprod Biol Endocrinol 2004, 10(2):10.
89. Takahashi Y., Li L., Kamiryo M., et al. Hyaluronan fragments induce endothelial cell differentiation in a CD44-and CXCL1/GRO1-dependent manner. J Biol Chem 2005, 280:24195-24204.
90. Triggs-Raine B., Salo T.J., Zhang H., Wicklow B.A., Natowicz M.R. Mutations in HYAL-1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci USA 1999, 96:6296-6300.
91. Udabage L., Brownlee G.R., Nilsson S.K., Brown T.J. The over-expression of HAS-2, HYAL-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005, 310:205-217.
92. Victor R., Chauzy C., Girard N. Human breast-cancer metastasis formation in a nude-mouse model, studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int J Cancer 1999, 82:77-83.
93. Zhang S., Chang M.C., Zylka D., et al. The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 1998, 273:11342-11348.